Lundbeck announces phase IIa study results of Lu AG06466 in adults with Tourette Syndrome
While there was insufficient efficacy to proceed with development of Lu AG06466 in Tourette Syndrome, the safety and tolerability of the agent was such that further investigational studies in additional indications will proceed. H. Lundbeck A/S (Lundbeck) today announced clinical results of a phase IIa investigational study with Lu AG06466 for the treatment of adult patients with Tourette Syndrome (TS). TS is a neuropsychiatric disorder characterized by sudden, involuntary, and repetitive motor and vocal tics often preceded by uncomfortable premonitory sensations (urges). The